Clinical Trials Logo

MCL clinical trials

View clinical trials related to MCL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06256484 Recruiting - Clinical trials for High-grade B-cell Lymphoma

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

NCT ID: NCT06192888 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Start date: January 8, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

NCT ID: NCT05788289 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.

NCT ID: NCT05414162 Recruiting - Multiple Myeloma Clinical Trials

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Start date: May 16, 2022
Phase:
Study type: Observational

Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.